Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel

Vanderbilt Muscle Study Vanderbilt University has registered a trial to test a supplement for preserving muscle in older adults starting semaglutide, a medication for type 2 diabetes and weight loss. On August 12, a phase 2 trial record appeared in ClinicalTrials.gov, involving 90 people aged 65–85 with type 2 diabetes, starting semaglutide, who will be randomly assigned to receive either a calcium form of HMB with vitamin D3 or a placebo for six months. During weight loss, lean tissue, including skeletal muscle, may also decrease, but muscles are essential for strength, walking, and independent living in older adults. In this trial, treating physicians will prescribe and manage semaglutide therapy, while the research team will compare the supplement to a placebo during the first six months of treatment. The trial will assess changes in lean body mass, measured using DXA scans, as well as hand and leg strength, six-minute walk distance, gait, and daily activity. The researchers will also use quantitative CT scans to evaluate muscle volume and composition, comparing changes in body composition to strength and movement. A separate part of the trial will involve up to 36 participants, using labeled creatine to assess contractile muscle tissue, and labeled amino acids and thigh muscle biopsies to provide data on muscle protein synthesis and breakdown. The combination of HMB and vitamin D3 has been previously tested in older adults in a randomized study, and Vanderbilt will now test it in people starting semaglutide, with data for the primary comparison expected to be collected by November 30, 2029, as reported in ClinicalTrials.gov. 🔗 Read original →